1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Psoriasis - Pipeline Review, H2 2020, provides an overview of the Psoriasis (Immunology) pipeline landscape.
Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared up skin, itchiness, and burning sensation, swollen and stiff joints. Predisposing factors include heredity, side effects of certain medicines, stress, infections and environmental conditions. The condition may be controlled by topical or systemic medications and phototherapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Psoriasis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Psoriasis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Psoriasis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 25, 38, 63, 2, 150, 40 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 5 molecules, respectively.
Psoriasis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriasis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Psoriasis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Psoriasis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Psoriasis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Psoriasis (Immunology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Psoriasis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Psoriasis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionPsoriasis - Overview
Psoriasis - Therapeutics Development
Psoriasis - Therapeutics Assessment
Psoriasis - Companies Involved in Therapeutics Development
Psoriasis - Drug Profiles
Psoriasis - Dormant Projects
Psoriasis - Discontinued Products
Psoriasis - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Psoriasis, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Psoriasis - Pipeline by 3SBio Inc, H2 2020
- Psoriasis - Pipeline by AbbVie Inc, H2 2020
- Psoriasis - Pipeline by Abcentra LLC, H2 2020
- Psoriasis - Pipeline by AbClon Inc, H2 2020
- Psoriasis - Pipeline by Abeome Corp, H2 2020
- Psoriasis - Pipeline by Abivax SA, H2 2020
- Psoriasis - Pipeline by Accuitis Pharmaceuticals Inc, H2 2020
- Psoriasis - Pipeline by Aclaris Therapeutics Inc, H2 2020
- Psoriasis - Pipeline by Actinobac Biomed Inc, H2 2020
- Psoriasis - Pipeline by ADiTx Therapeutics Inc, H2 2020
- Psoriasis - Pipeline by Aerie Pharmaceuticals Inc, H2 2020
- Psoriasis - Pipeline by Affibody AB, H2 2020
- Psoriasis - Pipeline by Philogen SpA, H2 2020
- Psoriasis - Pipeline by Polpharma Biologics, H2 2020
- Psoriasis - Pipeline by PRCL Research Inc, H2 2020
- Psoriasis - Pipeline by Precigen ActoBio Inc, H2 2020
- Psoriasis - Pipeline by Principia Biopharma Inc, H2 2020
- Psoriasis - Dormant Projects, H2 2020
- Psoriasis - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Psoriasis, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- AbbVie Inc
- Abcentra LLC
- AbClon Inc
- Abeome Corp
- Abivax SA
- Accuitis Pharmaceuticals Inc
- Aclaris Therapeutics Inc
- Actinobac Biomed Inc
- ADiTx Therapeutics Inc
- Aerie Pharmaceuticals Inc
- Affibody AB
- Affilogic SAS
- Akeso Inc
- Aldeyra Therapeutics Inc
- Allergy Therapeutics Plc
- Allianz Pharmascience Ltd
- Almirall SA
- AltruBio Inc
- Aluda Pharmaceuticals Inc
- Alvotech ehf
- AmDerma Pharmaceuticals LLC
- Amgen Inc
- Amicogen Inc
- AnaptysBio Inc
- Annji Pharmaceutical Co Ltd
- AntalGenics SL
- AnTolRx Inc
- Apidel SA
- Apimeds Inc
- Applied Biology Inc
- Arbor Pharmaceuticals LLC
- Arcutis Inc
- Arrien Pharmaceuticals LLC
- AstraZeneca Plc
- Athenex Inc
- Atlantic Bio Sci LLC
- Aurigene Discovery Technologies Ltd
- Avicanna Inc
- Avidin Biotechnology Ltd
- Bayer AG
- Beijing Fogangren Bio-Pharm Tech Co Ltd
- Beijing Guiqianjin Medical Technology Co Ltd
- Beijing Northland Biotech Co Ltd
- Beijing SH Bio-Tech Corp
- Better Life Pharmaceuticals Inc
- Bio-Thera Solutions Ltd
- BioApex sro
- Biocon Ltd
- BioLingus AG
- Biomendics LLC
- Biomimetix JV LLC
- BioXpress Therapeutics SA
- Biozeus Pharmaceutical SA
- BirchBioMed Inc
- Boehringer Ingelheim International GmbH
- Boston Pharmaceuticals Inc
- Botanix Pharmaceuticals Ltd
- Brickell Biotech Inc
- Bristol-Myers Squibb Co
- c-a-i-r Biosciences GmbH
- C4X Discovery Holdings Plc
- Can-Fite BioPharma Ltd
- Canvax Biotech SL
- CellionBioMed Inc
- Celltrion Inc
- Celon Pharma SA
- CheckPoint Immunology Inc
- ChemoCentryx Inc
- Chengdu Jinrui Foundation Biotechnology Co Ltd
- Chiesi Farmaceutici SpA
- Coegin Pharma AS
- Coherus BioSciences Inc
- Compugen Ltd
- Crescita Therapeutics Inc
- Curapel Ltd
- Cythera Inc
- Cytodyn Inc
- Daewoong Pharmaceutical Co Ltd
- Daiichi Sankyo Co Ltd
- Dalriada Therapeutics Inc
- DelArrivo Inc
- Denali Therapeutics Inc
- Dermavant Sciences Inc
- DiCE Molecules SV Inc
- DM Bio Ltd
- DNX Biopharmaceuticals Inc
- Dr. August Wolff GmbH & Co KG Arzneimittel
- Eli Lilly and Co
- ELORAC Inc
- Emeriti Pharma AB
- Enzychem Lifesciences Corp
- Eolo Pharma
- Escalier Biosciences BV
- Eternity Bioscience Inc
- Evelo Biosciences Inc
- Exicure Inc
- FunPep Co Ltd
- FYB202 GmbH & Co KG
- Galapagos NV
- Galderma SA
- Galectin Therapeutics Inc
- Genentech USA Inc
- GeneScience Pharmaceuticals Co Ltd
- Genesen Co Ltd
- Genfit SA
- Genrix (Shanghai) Biopharmaceutical Co Ltd
- GlaxoSmithKline Plc
- GlycoMar Ltd
- Helix BioMedix Inc
- Hengenix Biotech Inc
- HitGen Inc
- Huabo Biopharm Co Ltd
- Hualan Biological Engineering Inc
- Hydra Biosciences Inc
- ILC Therapeutics Ltd
- Iltoo Pharma
- IMGENEX India Pvt Ltd
- Immune Pharmaceuticals Inc
- ImmuneMed Inc
- Immungenetics AG
- Immunic Inc
- Immunwork Inc
- Impetis Biosciences Ltd
- InnoCare Pharma Ltd
- Innovimmune Biotherapeutics Inc
- InSight Biopharmaceuticals Ltd
- Inspyr Therapeutics Inc
- Instituto Biomar SA
- Io Therapeutics Inc
- Istesso Ltd
- Japan Tobacco Inc
- JHL Biotech Inc
- Jiangsu Carephar Pharmaceutical Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- JiangSu Qyuns Therapeutics Co Ltd
- Johnson & Johnson
- JS InnoPharm (Shanghai) Ltd
- Jubilant Therapeutics Inc
- Kadmon Corp LLC
- Kang Stem Biotech Co Ltd
- Kangpu Biopharmaceuticals Ltd
- Kine Sciences
- Krystal Biotech Inc
- Kv1.3 Therapeutics
- Kymab Ltd
- Lead Pharma Holding BV
- Leo Pharma AS
- Link Health Group
- Lipidor AB
- Livzon Pharmaceutical Group Co Ltd
- Luye Pharma Group Ltd
- Lycera Corp
- Mabpharm Ltd
- Machavert Pharmaceuticals LLC
- Maruho Co Ltd
- Matrisys Bioscience Inc
- MC2 Therapeutics AS
- Merck KGaA
- Metrion Biosciences Ltd
- MetrioPharm AG
- Mical Pharmaceuticals LLC
- Midatech Pharma Plc
- Mycenax Biotech Inc
- Nektar Therapeutics
- Nepsone ehf
- NeuClone Pty Ltd
- Nichi-Iko Pharmaceutical Co Ltd
- Nimbus Therapeutics LLC
- North China Pharmaceutical Group New Drug Research and Development Co Ltd
- NovaLead Pharma Pvt Ltd
- Novartis AG
- Numab Therapeutics AG
- OncoSynergy Inc
- One World Cannabis Ltd
- Orphagen Pharmaceuticals Inc
- OSE Immunotherapeutics
- P & S Nano Ltd
- Palo BioFarma SL
- Panaxia Pharmaceutical Industries Ltd
- Par'Immune SAS
- Pfizer Inc
- Pharmapraxis
- Philogen SpA
- Polpharma Biologics
- PRCL Research Inc
- Precigen ActoBio Inc
- Principia Biopharma Inc
- Progenra Inc
- Promethera Biosciences SA
- Protein Foundry LLC
- Protheragen Inc
- Provectus Biopharmaceuticals Inc
- Pyramid Biosciences Inc
- Reata Pharmaceuticals Inc
- Regeneus Ltd
- Regranion LLC
- Reliance Life Sciences Pvt Ltd
- Revive Therapeutics Ltd
- Rheos Medicines Inc
- Rigel Pharmaceuticals Inc
- RNAx Ltd
- Samumed LLC
- Sareum Holdings Plc
- SBI Biotech Co Ltd
- Servatus Ltd
- SFA Therapeutics LLC
- Shandong Danhong Pharmaceutical Co Ltd
- Shanghai Celgen Bio-Pharmaceutical Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shulov Innovative Science Ltd
- Siam Bioscience Co Ltd
- Sichuan Haisco Pharmaceutical Co Ltd
- Sienna Biopharmaceuticals Inc
- Singh Biotechnology LLC
- Sinocelltech Ltd
- siRNAgen Therapeutics Corp
- Sol-Gel Technologies Ltd
- Soligenix Inc
- Sparrow Pharmaceuticals Inc
- Spherium Biomed SL
- sterna biologicals Gmbh & Co KG
- Sun Pharma Advanced Research Company Ltd
- Sun Pharmaceutical Industries Ltd
- Sunny BioDiscovery Inc
- Suzhou Connect Biopharmaceuticals Ltd
- Syntrix Biosystems Inc
- Taro Pharmaceuticals USA Inc
- Temisis Therapeutics
- Tianjin Ever Union Biotechnology Co Ltd
- Tianjin Hemay Pharmaceutical Co Ltd
- Tonghua Dongbao Pharmaceutical Co Ltd
- UCB SA
- Union Therapeutics AS
- V Clinbio LLC
- Vidasym Inc
- Visionary Pharmaceuticals Inc
- Viva Vision Biotech
- Voronoi Group
- vTv Therapeutics Inc
- Welichem Biotech Inc
- Wellstat Therapeutics Corp
- WntResearch AB
- Wuhan Institute of Biological Products Co Ltd
- Xbrane Biopharma AB
- Zai Lab Ltd
- Zhejiang Hisun Pharmaceutical Co Ltd
